These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32507066)

  • 1. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis.
    Uppal SK; Kearns DG; Chat VS; Han G; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):626-636. PubMed ID: 32507066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
    Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
    Uppal SK; Chat VS; Kearns DG; Wu JJ
    J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
    Yang N; Chen Z; Zhang X; Shi Y
    BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of systemic treatments for atopic dermatitis.
    Seger EW; Wechter T; Strowd L; Feldman SR
    J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapies for atopic dermatitis: An update.
    Deleanu D; Nedelea I
    Exp Ther Med; 2019 Feb; 17(2):1061-1067. PubMed ID: 30679974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
    Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
    Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.
    Prajapati S; Fardos M; Desai AD; Feldman SR
    Immunotherapy; 2023 Sep; 15(13):981-991. PubMed ID: 37401345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.
    Picone V; Vallone Y; Patruno C; Napolitano M
    Expert Rev Clin Pharmacol; 2023; 16(12):1239-1248. PubMed ID: 38054328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
    Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.
    Loh TY; Hsiao JL; Shi VY
    J Asthma Allergy; 2020; 13():109-114. PubMed ID: 32104006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of nemolizumab in the treatment of atopic dermatitis for the adult population.
    Prajapati S; Flemming JP; Khan D; Han H; How B; Rozenberg SS; Feldman SR
    Immunotherapy; 2024; 16(14-15):925-935. PubMed ID: 39119679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective IL-13 inhibitors for the treatment of atopic dermatitis.
    Gonçalves F; Freitas E; Torres T
    Drugs Context; 2021; 10():. PubMed ID: 33889195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018.
    Werfel T
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):432-437. PubMed ID: 30095475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
    Butala S; Castelo-Soccio L; Seshadri R; Simpson EL; O'Shea JJ; Bieber T; Paller AS
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1361-1373. PubMed ID: 36948491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of biologics in atopic dermatitis.
    Wu J; Guttman-Yassky E
    Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
    [No Abstract]   [Full Text] [Related]  

  • 17. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
    Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
    Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of biologic drugs in children or adolescents with atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
    Felix de Farias Santos AC; Zamora FV; Galvao LKCS; Pimenta NDS; Salles JPCEA; Heffel KK
    Australas J Dermatol; 2024 Nov; 65(7):550-559. PubMed ID: 39101303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
    Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.